Title:
THERAPEUTIC AGENT FOR NON-MOTOR SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE
Document Type and Number:
WIPO Patent Application WO/2018/131672
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonin nervous system- or dopamine nervous system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonin nervous system- or dopamine nervous system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same.
Inventors:
KATO TARO (JP)
SHIMIZU SATOKO (JP)
SHIMIZU SATOKO (JP)
Application Number:
PCT/JP2018/000568
Publication Date:
July 19, 2018
Filing Date:
January 12, 2018
Export Citation:
Assignee:
SUMITOMO DAINIPPON PHARMA CO LTD (JP)
International Classes:
A61K31/415; A61K31/4155; A61K45/00; A61P25/16; A61P25/18; A61P25/20; A61P25/22; A61P25/24; A61P25/28; A61P43/00
Domestic Patent References:
| WO2012008528A1 | 2012-01-19 | |||
| WO2012008528A1 | 2012-01-19 |
Foreign References:
| JP2006504794A | 2006-02-09 | |||
| JP2008546691A | 2008-12-25 | |||
| JP2010505832A | 2010-02-25 |
Other References:
J. M. RABEY, PARKISONISM AND RELATED DISORDER, vol. 155, 2009, pages 105 - 1110
A. BREIER, BIOL. PSYCHIATRY, vol. 52, no. 5, 2002, pages 438 - 445
W. G. ONDO, MOV. DISORD., vol. 17, no. 5, 2002, pages 1031 - 1035
J. C. GOMEZ-ESTEBAN, CLIN. NEUROPHARMACOL., vol. 28, no. 7, 2005, pages 111 - 114
P. POLLAK, J. NEUROL. NEUROSURGE. PSYCHIATRY, vol. 75, no. 5, 2004, pages 689 - 695
J. CUMMINGS, LANCET, vol. 383, 2014, pages 533 - 40
K. E. VANOVAR, J. PHARMACOL. EXP. THERAPEUTICS: JPET, vol. 317, 2006, pages 910 - 918
P. MARTINEZ-MERTIN, EUR. J. NEUROLOGY, vol. 22, 2015, pages 37 - 43
W. DUNCUN, MOVEMENT DSIORDER, vol. 29, no. 2, 2014, pages 195 - 202
"Clinical Practice Guideline for Parkinson's disease", 2011
D. GARCIA-BORREGUERO, SLEEP MEDICINE REVIEWS, vol. 7, no. 2, 2003, pages 115 - 129
M. EMRE, LANCET NEUROLOGY, vol. 2, 2003, pages 229 - 37
S. OBERNDORFER, NEUROPSYCHOBIOLOGY, vol. 42, 2000, pages 69 - 81
H. P. LANDOLT, EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 29, 2009, pages 1795 - 1809
B. AVLAR, BEHAV NEUROSCI., vol. 129, no. 5, 2015, pages 576 - 588
G. J. MAREK, NEUROPSYCHOPHARMACOLOGY, vol. 28, 2003, pages 402 - 412
J. P. RENERIC, BEHAVIOURAL BRAIN RESEARCH, vol. 136, 2002, pages 521 - 532
J. ANDERSEN, ACTA NEURAL SCAND., vol. 62, no. 4, 1980, pages 210 - 219
P. VIJAYAPANDI, YAKUGAKU ZASSHI, vol. 125, no. 8, 2005, pages 653 - 657
H. A. HANAGASI, FUNDAMENTAL & CLINICAL PHARMACOLOGY, vol. 19, 2005, pages 133 - 146
HILL A. V., J. PHYSIOL., vol. 40, 1910, pages 190 - 200
OWENS M. J. ET AL., J. PHARM. EXP. THER., vol. 283, 1997, pages 1305 - 1322
See also references of EP 3569233A4
A. BREIER, BIOL. PSYCHIATRY, vol. 52, no. 5, 2002, pages 438 - 445
W. G. ONDO, MOV. DISORD., vol. 17, no. 5, 2002, pages 1031 - 1035
J. C. GOMEZ-ESTEBAN, CLIN. NEUROPHARMACOL., vol. 28, no. 7, 2005, pages 111 - 114
P. POLLAK, J. NEUROL. NEUROSURGE. PSYCHIATRY, vol. 75, no. 5, 2004, pages 689 - 695
J. CUMMINGS, LANCET, vol. 383, 2014, pages 533 - 40
K. E. VANOVAR, J. PHARMACOL. EXP. THERAPEUTICS: JPET, vol. 317, 2006, pages 910 - 918
P. MARTINEZ-MERTIN, EUR. J. NEUROLOGY, vol. 22, 2015, pages 37 - 43
W. DUNCUN, MOVEMENT DSIORDER, vol. 29, no. 2, 2014, pages 195 - 202
"Clinical Practice Guideline for Parkinson's disease", 2011
D. GARCIA-BORREGUERO, SLEEP MEDICINE REVIEWS, vol. 7, no. 2, 2003, pages 115 - 129
M. EMRE, LANCET NEUROLOGY, vol. 2, 2003, pages 229 - 37
S. OBERNDORFER, NEUROPSYCHOBIOLOGY, vol. 42, 2000, pages 69 - 81
H. P. LANDOLT, EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 29, 2009, pages 1795 - 1809
B. AVLAR, BEHAV NEUROSCI., vol. 129, no. 5, 2015, pages 576 - 588
G. J. MAREK, NEUROPSYCHOPHARMACOLOGY, vol. 28, 2003, pages 402 - 412
J. P. RENERIC, BEHAVIOURAL BRAIN RESEARCH, vol. 136, 2002, pages 521 - 532
J. ANDERSEN, ACTA NEURAL SCAND., vol. 62, no. 4, 1980, pages 210 - 219
P. VIJAYAPANDI, YAKUGAKU ZASSHI, vol. 125, no. 8, 2005, pages 653 - 657
H. A. HANAGASI, FUNDAMENTAL & CLINICAL PHARMACOLOGY, vol. 19, 2005, pages 133 - 146
HILL A. V., J. PHYSIOL., vol. 40, 1910, pages 190 - 200
OWENS M. J. ET AL., J. PHARM. EXP. THER., vol. 283, 1997, pages 1305 - 1322
See also references of EP 3569233A4
Attorney, Agent or Firm:
SAMEJIMA, Mutsumi et al. (JP)
Download PDF:
Previous Patent: ROTATING ELECTRIC MACHINE
Next Patent: NOVEL TISSUE REGENERATION MATERIAL AND METHOD FOR PRODUCING SAME
Next Patent: NOVEL TISSUE REGENERATION MATERIAL AND METHOD FOR PRODUCING SAME